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Summary Early and severe loss of body weight associated with pronounced tissue changes developed in rats
transplanted with a fast-growing ascites hepatoma (Yoshida AH-130). The protein content showed an early
and marked fall in the skeletal muscle, while in the liver it transiently increased 4 days after implantation then
declined to values lower than in control animals. Protein loss in gastrocnemius muscle and liver resulted
mainly from enhancement of protein catabolism (Tessitore L. et al., Biochem. J., 241: 153-158, 1987). In
contrast to the tumour-bearing rats, in the pair-fed animals the initial body weight was maintained, while the
protein mass decreased sharply in the liver and moderately in the grastrocnemius muscle. In host animals total
plasma protein decreased during the period of tumour growth, while both triglycerides and total cholesterol
markedly increased. Glucose remained unchanged even when overt cachexia had developed. The total free
amino acid concentration in the plasma of tumour-bearing rats decreased slightly by day 4 and returned to
values close to those of controls in the late stages of tumour growth. By contrast, in the pair-fed controls the
plasma levels of triglycerides and particularly of total free amino acids and glucose decreased over the whole
experimental period, whereas total protein and cholesterol were unchanged. Marked perturbations in the
hormonal homeostasis developed early after tumour transplantation. The plasma levels of glucagon, cor-
ticosterone and catecholamines rose sharply, while those of insulin and thyroid hormones decreased. Further-
more, high plasma concentrations of prostaglandin E2 (PGE2) and tumour necrosis factor (TNF) were
observed over the whole experimental period. IL-I-like activity, TNF and PGE2 were released in vitro from
AH-130 cells. These data suggest that the systemic effects of AH-130 tumour on the host rat reflected the
interplay of a complex network of factors, including classical hormones and cytokines, all of which likely
concur in enhancing tissue protein catabolism.
Cachexia frequently accompanies advanced or terminal can-
cer states, though it can also develop early in the course of
neoplastic diseases (Shapot, 1979; Lawson et al., 1982; Kern
& Norton, 1988; Morrison, 1989). The underlying mechan-
isms are not well understood, either in humans or in experi-
mental animals.
In the early phases of tumour growth the total protein
mass of the body is usually preserved, even though nitrogen
can be already redistributed out of host tissues and diverted
to the tumour (Lawson et al., 1982). In overt cachexia, loss
of lean body weight primarily reflects waste of tissue pro-
teins, particularly from skeletal muscles (which account for
almost half of the protein mass in the body). Tissue protein
waste implies a negative balance between anabolic and
catabolic processes. In this regard hypophagia and protein-
calorie malnutrition can play an important role (Kern &
Norton, 1988; Morrison, 1989), yet most often parenteral or
over-feeding are only transiently and partially effective in
combating cancer cachexia (Theologides, 1972; Bozzetti et
al., 1987). The view that protein depletion may primarily
reflect enhanced protein turnover has been recently supported
by both experimental (Tayek et al., 1986, 1988; Tessitore et
al., 1987a; Beck & Tisdale, 1989) and clinical evidence (Kien
& Camitta, 1983, 1987; Fearon et al., 1988; Melville et al.,
1990; Beck et al., 1991).
We have previously shown that growth of the ascites
hepatoma Yoshida AH-130 in rats elicits an early and con-
spicuous loss of body weight, associated with a protein
hypercatabolic state in host tissues (Tessitore et al., 1987a).
The initial changes are already manifest at a tumour burden
not exceeding 0.1% of the host body weight; this figure is
significantly lower than the tumour burden usually observed
to cause cachexia in most experimental models, yet not far
from that observed in humans (cf. Morrison et al., 1984;
Pisters & Brennan, 1990). This experimental model thus
appears particularly appropriate to investigate the mechan-
isms involved in tumour associated cachexia.
In the present study we have evaluated some systemic
effects of the Yoshida AH-130 tumour on the host, focusing
on factors which may affect tissue protein metabolism. We
report here that marked perturbations in the hormonal
homeostatis and occurrence of cytokine-like factors are elici-
ted soon after implanting the AH-130 tumour. Moreover, the
tumour cells themselves are able to release cytokines such as
TNF and IL-l as well as PGE2. All these events are likely to
play a significant role in forcing protein metabolism in host
tissues into a hypercatabolic state. Therefore, the present
data further support the hypothesis (Tessitore et al., 1987a)
that protein depletion in these tumour hosts mainly reflects
an 'active' loss rather than just impoverishment due to
reduced food uptake or metabolic competition by the tum-
our.
Material and methods
Animals and tumours
Male Wistar rats (Nossan, Milano, Italy) weighing about
200 g were maintained on a regular light-dark cycle (light
08:00-20:00) and had free access to a balanced semi-syn-
thetic diet (Piccioni, Brescia, Italy) and water. The Yoshida
ascites hepatoma AH-130 was maintained by weekly intra-
peritoneal transplantation of approx. 3 10' cells, while for the
experiments rats were injected with 108 cells from exponential
tumours (Tessitore et al., 1987a). The animals were divided
into two groups (ad libitum fed controls and transplanted) of
comparable body weight. In some experiments, a third group
of pair-fed controls was added. The amount of food con-
sumed by individually housed rats was calculated every day
by weighing the food that remained by 12 a.m. Skin and
rectal temperatures were measured with a digital thermo-
meter. Just before killing, the animals were weighed and
anaesthetised with diethyl ether to collect the blood from the
aorta into heparinised tubes. Platelet-poor plasma obtained
by centrifugation (3500 g for Omin at 4'C) was immediately
aliquoted for storage at - 80°C. Tumour wet weight, volume
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and cellularity were measured. In some experiments tissues
were homogenised to 1:10 (w/v) in chilled distilled water with
a Turrax apparatus (Janke & Kunkel, Ika-Werk, Staufen,
Germany), then sonicated (2 x 30 s), centrifuged at 4°C and
frozen in aliquots at - 80°C. Samples used for amino acid
determination were previously deproteinised with sulphosali-
cyclic acid.
Assays
Protein was determined as previously reported (cf. Baccino et
al., 1982), triglycerides with the kit Triglycerides GPO Rea-
gent (Biorad, Richmond, CA, USA), glucose with the kit
Glu-Cinet (Sclavo S.p.a., Siena, Italy), calcium with the Uni-
kit II (Roche, Basel, Switzerland), and total cholesterol with
a kit from Boehringer, Mannheim, Germany. Amino acids
were evaluated using an amino acid analyser (Kontron
Instruments, Zurich, Switzerland) by the method of Moore &
Stein (1951). Blood plasma hormones were measured by
radioimmunoassay using commercially available kits: Insulin
radioimmunoassay (Corning, Medfield, MA, USA), total T3
and T4 (Lepetit, Milano, Italy), Ria-mat Glucagon (Mallin-
ckrodt, Dietzenbach, Germany). Corticosterone was evalua-
ted by a competitive protein-binding assay (Angeli et al.,
1975). Free catecholamines in plasma and urine were deter-
mined by HPLC using a kit from Biorad, Richmond, CA,
USA. To assay PGE2, prostanoids were separated by HPLC
(Nigan et al., 1985). TNF was determined either by an
ELISA test (Genzyme, Cambridge, MA, USA) or with the
L929 cell toxicity assay (Flick & Gifford, 1984); one unit of
activity was defined as the reciprocal dilution required to
produce a 50% decrease in absorbance relative to control
cells exposed to actinomycin D alone. IL-1 activity was
measured using the mouse thymocyte proliferation assay
(Cannon & Dinarello, 1985); one unit of activity was defined
as the reciprocal of the dilution required to produce a 50%
increase in stimulation index relative to thymocytes exposed
to phytohaemagglutinin alone.
Cell cultures
Peripheral blood monocytes/macrophages, isolated from con-
trol and tumour-bearing rats as previously reported (Tes-
sitore et al., 1987b), were cultured for 24 h in RPMI medium
containing 10% FCS in the presence or in the absence of
5figml-' of E. coli LPS (Sigma, St. Louis, MO, USA). At
the end of the incubation the culture medium was tested for
the presence of IL-1 and TNF bioactivities.
Short term cultures of AH-130 tumours were performed
with cells harvested from animals under sterile conditions,
washed, resuspended in DMEM containing 10% FCS at the
concentration of 106 ml-', and incubated for 24 h at 370C.
The culture medium was then collected and IL-i-like activity
and TNF measured; 20 mM indomethacin was added to the
samples used to evaluate the PGE2 production. In some
experiments, the inflammatory cells contaminating the ascites
tumour were separated by adhesion to a glass surface as
previously reported (Tessitore et al., 1987c); the two popula-
tions thus obtained, namely, peritoneal macrophages and
AH-130 cells, were incubated as described above.
The release of PGE2 from muscle was evaluated incubating
the soleus in the extended position for 3 h in Krebs-Ringer
bicarbonate buffer at 370C. To block de novo synthesis of
PGE2, 20 mM indomethacin was added at the end of the
incubation and the samples frozen.
Statistical analysis
Data are presented as means ± s.d. The significance of
differences has been evaluated by analysis of variance.
Results
Body and tissue weight
As previously reported (Tessitore et al., 1987a), with an
intraperitoneal inoculum of 108 cells the tumour maintained
exponential growth for about 6 days; growth then subsided,
attaining a quasi-stationary phase by day 8 (Figure 2a).
Death of the animals occurred about 15 days after transplan-
tation. In the present work two time points were selected for
most experiments; day 4, for the middle of the log phase of
tumour growth, and day 10, for the fully established sta-
tionary phase. The daily food intake per animal amounted to
18-20 g for ad libitum fed controls, but after tumour
implantation it gradually declined from 18 g on day 0 to
about 10 g on day 10 (then dropping to 3 g on day 12 and
about 0 g at day 14). The water intake was quite similar
(about 25 ml/day) for controls and tumour-bearing animals
over the whole experimental period. Thus in many experi-
ments we included a third group of rats, the pair-fed con-
trols, which received food in the same amount as ingested by
tumour bearers.
In tumour-bearing rats the body weight, excluding the
ascites tumour, steadily declined to about half the control
values on day 10 (Figure 1). In the present study we focused
our attention on two tissues that showed the most prominent
changes (cf Tessitore et al., 1987a): the gastrocnemius muscle
(Figure 2c), showing a progressive, marked fall in protein
content, and the liver (Figure 2b), which manifested first a
rise, then a fall in protein content. Gastrocnemius wasting
and changes in other tissues (data not shown) were already
manifest when the tumour mass attained approximately 0.1%
of the body weight (day 2), while severe cachexia developed
at day 10, when the tumour burden approximated 5% of the
body weight.
Additional information on the metabolic state of tumour
hosts is provided by data shown in Figures 3 and 4. The
blood plasma concentration of glucose (Figure 3) did not
significantly change over the whole experimental period,
though it was constantly very low (1-2 mg dl-') in the ascitic
fluid; thus glucose homeostatis was adequate to maintain
normal plasma levels of this sugar in spite of its extensive
utilisation by tumour cells. Plasma total protein (Figure 3)
and albumin (not shown) substantially decreased during
tumour growth and the protein content of the ascitic fluid
remained close to that of plasma (not shown). The total
plasma level of free amino acids (Figure 4) was decreased
when the tumour was actively proliferating, then returned to
250 t
4-
._- g60
3: -a 150 -
50 -
T T
-
-- -
T
A
\ T T
* 01 -0
I
0 2 4 6 8 10
Days after transplantation
Figure 1 Body weight of (A) ad libitum-fed controls, (0) pair-
fed controls, and (0) tumour-bearing rats. Vertical bars denote
s.d.; n=4.
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Figure 2 Tumour protein mass A and protein content of liver B
and gastrocnemius muscle C in tumour hosts (closed symbols)
and in pair-fed controls (open symbols). Data are given as total
protein per tumour or, for liver and gastrocnemius, as total
protein per organ expressed as percentage of the corresponding
average to value. Vertical bars denote s.d.; n = 4. Significance of
the differences: a = P<0.05 vs day 0, b = P<0.05 vs day 4,
c=P<0.05 vs the same time, d=P<0.01 vs day 0, e=P<
0.01 vs the same time.
values close to those of controls when the animals were most
cachetic. Total cholesterol (Figure 3) showed a sustained and
progressive increment in the blood plasma, in agreement with
previous observations (Grunfeld et al., 1989; Stovroff et al.,
1989); this increase has been shown to be associated with
elevation of low-density lipoprotein cholesterol and reduction
of high-density lipoprotein cholesterol (Dessi et al., 1992).
The steady increase in triglycerides (Figure 3) was consistent
(cf. Beutler & Cerami, 1988; Sherman et al., 1988; Sherry et
al., 1989) with the observed sustained increase of TNF in
tumour-bearing animals (see below). Also suggesting a
release of cytokines was the increase of the rectal (Table I)
and skin (not shown) temperature during the first days after
tumour transplantation, although this was followed by a
progressive fall to subnormal values in later stages.
In the group of pair-fed controls, undernutrition was
severe enough to cause significant metabolic changes. The
rats did not gain body weight during the experimental period
(Figure 1). The gastrocnemius muscle also sustained some
protein loss, though much less pronounced than in tumour
bearers (Figure 2c); the hepatic protein mass markedly
decreased, reaching values that at day 10 were even lower
than in tumour bearers (Figure 2b). The protein-calorie
restriction also caused a persistent hypoglycemia (Figure 3),
in contrast with the normal values in tumour bearers. Total
free amino acids (Figure 4) were slightly decreased in the
pair-fed controls, while in tumour hosts plasma amino acids
returned to normal levels at day 10. Triglycerides (Figure 3)
slightly declined in the pair-fed group, but were markedly
elevated in tumour bearers. Finally, the pair-fed rats did not
develop any significant alteration in the blood plasma levels
of protein and cholesterol (Figure 3), contrasting with their
falling and rising pattern, respectively, in tumour hosts.
Hormones and other humoralfactors
Several hormones and other humoral agents are known to be
potential modifiers of protein metabolism in peripheral tis-
sues (Waterlow, 1984) and thus are possible candidates as
positive or negative effectors of the hypercatabolic state in
AH-130 tumour hosts. The blood plasma levels of a number
of such agents after tumour implantation in rats are listed in
Table I, showing that multiple and pronounced alterations of
the endocrine status developed in these animals. Insulin
markedly declined to less than half of the normal values by
day 4 and remained at this level until the end of the experi-
mental period (as predictable, it was also reduced in pair-fed
animals [data not shown; cf. Lagopoulos et al., 1991]). Recip-
rocally, by day 4 glucagon reached values 4-6-fold higher
than in controls. T3 and, particularly, T4 were reduced by day
3, down to about half and one fourth of control values,
respectively. Corticosterone was elevated by day 4, but
returned to control levels on day 10. The plasma levels of
norepinephrine and epinephrine were markedly increased by
day 4 and even more so at day 10. The concentration of free
urinary catecholamines showed a progressive increase up to
day 9 (Figure 5).
TNF was detected both as bioactivity (data not shown)
and as immunoreactive protein in the plasma of tumour-
bearing rats since the first day after transplantation, peaking
at day 4 (Table I; assay sensitivity about 1O pg ml-'). PGE2,
a putative enhancer of muscle protein catabolism (Rodemann
& Goldberg, 1982a; Strelkov et al., 1989), was also increased
(Table I). Calcium has also been suggested to stimulate mus-
cle protein catabolism (cf. Rodemann et al., 1982b): its in-
crease in the blood plasma has been observed in animals
after treatment with IL-1 and TNF (Sabatini et al., 1988,
1990) and in cancer patients (Tashjian et al., 1974); we did
not, however, detect any change in calcium in AH-130
tumour hosts (Table I).
Further experiments were designed to determine the cel-
lular origin of plasma TNF and PGE2 in tumour-bearing
rats. Two possible sources were considered: (1) circulating
and peritoneal mononuclear phagocytes or (2) the tumour
cells themselves. As shown in Table II, the presence of the
tumour at day 4 did not modify the ability of blood
monocytes to release TNF in vitro upon challenge with LPS,
yet strongly depressed it at day 10; on the other hand, blood
monocytes at day 4 released TNF even when cultured in the
absence of LPS, suggesting some degree of cell activation. By
contrast, the release of IL-1 was not affected, either in the
presence or in the absence of LPS (Table II). As for the
alternative hypothesis, the AH-130 hepatoma cells released
appreciable amounts of PGE2 (Figure 6), in agreement with
previous reports (Strelkov et al., 1989; Trevisani et al., 1980;
also see Tanaka et al., 1989). Of special interest was the
finding that in short-term culture these tumour cells released
significant amounts of TNF as well as of IL-1 (Figure 6).
This release was higher for exponential than for stationary
tumour cells, while the release of PGE2 showed an opposite
pattern (Figure 6). Consistently, TNF could be detected in
the ascitic fluid at concentrations higher at day 4 than at day
10 (143 ± 9 and 49 ± 5 pg ml-, respectively). Because reac-
tive leukocytes are an ordinary contaminant of this ascites
tumour, amounting to about 5% in the first days of growth
(cf. Tessitore et al., 1987c), we measured their contribution to
the observed release of cytokines. As shown in Table III,
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Figure 3 Blood plasma constituents in tumour hosts (closed symbols) and in pair-fed controls (open symbols). Vertical bars denote
s.d.; n = 5. Significance of the differences: a = P<0.05 vs day 0, b = P<0.05 vs the same time, c = P<0.01 vs day 0, d = P<0.0I
vs the same time.
less than half that of controls (Figure 7), in agreement with a
previous report (Strelkov et al., 1989).
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Figure 4 Total plasmatic level of free amino acids in tumour
hosts (closed symbols) and in pair-fed controls (open symbols).
Vertical bars denote s.d.; n = 4. Significance of the differences:
a = P<0.05 vs day 0, b = P<0.01 vs day 0, c = P<0.01 vs day
4.
however, the production of IL-1 activity and TNF by
purified macrophages separated from the whole ascites tu-
mour at day 4 was considerably lower than that by the
tumour cells alone. It can be noted that the release of TNF
from peritoneal macrophages (Table III) was of the same
order of the spontaneous release from blood monocytes at
day 4 (Table II), while the release of IL-1 from peritoneal
macrophages (Table III) was comparable to that from LPS-
stimulated blood monocytes (Table II). In a final experiment
we evaluated the possible role of muscle tissue in the rise of
PGE2. The soleus muscle from AH-130-bearing rats at days 4
and 10 released PGE2 into the incubation medium at a rate
Discussion
Hostprotein depletion
Tissue protein depletion is a central feature in cancer ca-
chexia, yet its underlying mechanisms are still debated.
Among the explanations most commonly proffered, the
'metabolic competition' theory maintains that neoplastic cells
effectively compete with host tissues for amino acids, acting
as a nitrogen trap. An alternative 'malnutrition' theory
envisages protein loss mostly as a consequence of protein-
calorie malnutrition, particularly due to hypophagia and/or
malabsorption. A third view, the 'humoral mediation' theory,
proposes that the relevant metabolic perturbations are
affected by circulating factors, directly released by tumour
cells and/or generated by the host reaction to the tumour.
We have previously shown that cachexia with an early onset
and a rapidly progressive course occurs in rats transplanted
with the ascites hepatoma Yoshida AH-130 and is charac-
terised by marked perturbations in tissue protein catabolism
(Tessitore et al., 1987a). The present paper further develops
the analysis of such a model and these observations, taken
together with previous findings, provide some insight into the
mechanisms involved.
Although undernutrition and tumour-host metabolic com-
petition are real occurrence and certainly deserve considera-
tion as factors in cancer-associated cachexia, the weight of
evidence supports the crucial role of humoral factors (perturb-
ed endocrine homeostastis, production of cytokines) in effect-
ing the hypercatabolic state in host tissue protein. Even when
the tumour burden is very low (0.1-0.2% of body weight),
cachexia begins to develop in AH-130-bearing rats, indicating
that metabolic competition alone cannot account for tissue
wasting. Similar observations have been made on different
types of neoplasms in patients developing cachexia (Mor-
rison, 1989; Pisters & Brennan, 1990). An early negative
nitrogen balance has been demonstrated in both humans and
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Table I Blood plasma levels of hormones and other factors and body temperature in AH-130 tumour-bearing rats
Days after tumour transplantation
0 1 2 3 4 10
Insulin (uUml-') 59 13 47 8 50 7 50 8 26 7a 17 7a
Glucagon (pg ml ) 163 15 100 36a 574+ 103b 548+ 13lb
T3 (pg ml ) 455 11 450 75 433 36 273 60b 242 73b 285 94b
T4 (ng ml ') 51 8 44 6 42 2 18 6b 12 4b 14+ 4
Corticosterone (ngml ') 210 60 330±32a 370±24a 330±31a 370±80a 230 72
Norepinephrine (pg ml ') 370 97 853 ± 286a 1352 393b
Epinephrine (pg ml-') 32±3 198±33* 431±88b
PGE2 (pgml') 10±3 19 5a 56±6b
TNF (pgml-') n.d. 26±4 11±3 30±2 80±8 50 5c
Calcium (jugml') 102 5 - - 92 3a 96 1
Rectal temperature (°C) 37.2 ± 0.1 37.2 + 0.2 37.4 ± 0.1 38.1 + 0.2a 38.0 O.la 35.9 0.3b
For full details see the Material and methods section. Values are means ± s.d. (n = 4 to 6); n.d. = not detectable; - = not tested. Significance
of the differences: ap<0.05, bP<0.01 vs day 0, cP<0.01 vs day 4.
(Tessitore et al., 1987a) and present observations on rats
transplanted with the AH-130 Yoshida ascites hepatoma:
early cachexia is associated with enhanced tissue protein
catabolism. On the other hand, a comparison of fractional
rates of protein synthesis and degradation in tumour cells vs
host tissues (Tessitore et al., 1987c) indicated that tumour
cells have a definite selective advantage, particularly on the
catabolic side of protein turnover. As a consequence, the I
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Figure 5 Free urinary catecholamines in tumour-bearing rats.
Vertical bars denote s.d.; n = 4.
0
Table II Release of IL-I and TNF from blood monocytes
Tumour bearers
Controls day 4 day J0
IL-1 (U 106 cells)
- LPS n.d. n.d. n.d.
+LPS 7.1 ± 1 5.7±0.9 6.5 1
TNF (pg 10-6 cells)
- LPS n.d. 174 19 16+4a
+ LPS 1094 ± 96 956 88 98 13b
Cells incubated in the absence or in the presence (5jigml-') of
LPS. Data (means ± s.d., n = 4) expressed as total IL-I activity or
TNF released in 24 h; n.d. = not detectable. Significance of the
differences: aP<0.01 vs day 4, bP<0.01 vs controls and vs day 4.
For full details see the Material and methods section.
animals under the influence of a variety of cancers (Kern &
Norton, 1988; Theologides, 1972). Studies performed on mice
bearing the MAC16 colon adenocarcinoma, a cachexia-
inducing tumour, have shown an elevated nitrogen loss dur-
ing early tumour growth (Beck & Tisdale, 1989). Moreover, a
number of reports have pointed out that enhanced tissue
protein degradation or acceleration in whole body protein
turnover make a substantial contribution to the protein waste
in tumour-bearing patients (Kien & Camitta, 1983, 1987;
Fearon et al., 1988; Melville et al., 1990; O'Keefe et al., 1990)
and experimental animals (Tayek et al., 1986, 1988; Tessitore
et al., 1987a; Beck & Tisdale, 1989; Beck et al., 1991; Pain et
al., 1984). Consistent with these reports are our previous
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Figure 6 Release of PGE2, IL-1, and TNF from logarithmic
(day 4) and stationary (day 10) AH-130 cells. Data expressed as
total amounts released per 106 cells/24 h. For full details see the
Material and methods section. Vertical bars denote s.d.; n = 4.
Significance of the differences: * = P<0.01 vs day 4.
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Table III Release of IL-1 and TNF from exponential AH-130
tumour cells and peritoneal macrophages
Total cells Tumour cells Macrophages
IL-1 (U 10-6 cells) 27 ± 2 20 ± 2 4.1 ± 0.06
TNF (pg 10-6 cells) 1150±42 904±23 325± 39
Data (means + s.d., n = 4) are expressed as total IL-1 activity or
TNF released in 24 h. Total cells = total ascites cells as harvested
from the peritoneal cavity; tumour cells = AH-130 cells only;
macrophages = peritoneal macrophages only. For full details see the
Material and methods section.
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Figure 7 Release of PGE2 from soleus muscle in tumour-bearing
rats. Data expressed as pg of PGE2 released per mg wet weight/h.
For full details see the Material and methods section. Vertical
bars denote s.d.; n = 4. Significance of the differences: *=P<
0.01 vs day 0.
AH-130 cells clearly have the ability to grow, or at least to
maintain a stationary state, though overall in the host pro-
tein catabolism predominates, particularly in some tissues.
Thus, the protein metabolic perturbations in the host, while
causing tissue waste, may as a consequence favour the
tumour growth by providing the necessary nitrogen for pro-
tein in the tumour (cf. Beck et al., 1991).
After AH-130 tumour implantation, the food intake of the
host rats progressively declined. Although such a decline was
sufficient to cause significant metabolic alterations in pair-fed
controls, the resulting overall pattern was quite different
from that in tumour hosts. Pair-fed controls developed a
typical pattern of partial starvation (Waterlow et al., 1978;
Baccino et al., 1982; Arnal et al., 1987), presenting with
relative loss of body weight (no body weight change com-
pared to the gain in ad libitum-fed animals), actual protein
loss from both gastrocnemius muscle and liver, and per-
sistently reduced plasma concentrations of glucose and total
free amino acids. In tumour-bearing animals, however, the
body weight progressively declined, protein loss in the gas-
trocnemius was considerably more pronounced, total liver
protein first increased at day 4 and then declined at day 10,
yet remaining higher than in pair-fed controls. Moreover,
tumour hosts did not develop hypoglycemia, at least until
day 10, and their plasma concentration of total free amino
acids, though initially decreased, returned to normal levels by
day 10. Plasma lipids also showed marked differences, tri-
glycerides and total cholesterol being increased in tumour
hosts only. On the basis of such observations, hypophagia
should be ruled out as a major determinant of the metabolic
patterns that characterise AH-130-bearing rats, at least in
early stages. Yet undernutrition undoubtedly occurs in these
tumour hosts, thus adding a further component to the com-
plexity of their metabolic perturbations. Studying a different
model of cachexia, Mulligan & Tisdale (1991) have recently
shown that only tumour-bearing animals that failed to adjust
their food intake in the presence of metabolic disturbances
underwent dramatic weight loss.
Humoral mediators
Altered hormonal levels as well as factors produced by host
or tumour cells likely combine to cause cancer cachexia.
Some of the systemic effects in cancer hosts have been as-
cribed to non-dialyzable circulating lipolytic and proteolytic
factors produced by the tumour (Beck & Tisdale, 1987; Beck
et al., 1990), which is consistent with the parabiotic transfer
of cachexia reported by Norton et al. (1985). High plasma
levels of catabolic hormones, low levels of insulin, and
insulin resistance of peripheral tissues are among the factors
most commonly considered as a cause of cancer cachexia
(Lawson et al., 1982; Morrison, 1989). However, it has been
suggested that hormonal changes could rather reflect an
adaptation to the metabolic alterations that lead to cachexia
(Svaninger et al., 1987a,b,c). In rats bearing the AH-130
tumour a whole spectrum of hormonal alterations have been
observed which may enhance tissue protein degradation:
insulin was decreased (cf. Goodlad et al., 1975) while coun-
ter-regulatory hormones such as corticosterone (cf. Goldberg,
1969; Odedra & Millward, 1984; Legaspi et al., 1985),
glucagon (cf. Kibler et al., 1964) and catecholamines (cf. Van
Gool et al., 1984) were elevated. The high level of cor-
ticosterone at day 4 well correlated with enlarged adrenal
glands and an associated hypertrophic/hyperplastic histo-
logical pattern. As an apparent exception to the hyper-
catabolic endocrine pattern, the low plasma concentrations of
thyroid hormones might be expected to play an opposite role
(Morrison et al., 1988). However, a reduction of T3 and T4
does not necessarily imply a decrease in thyroid biological
activity, as shown by Kumara-Siri et al. (1981): rats bearing
the Walker 256 carcinoma have low concentrations of T3 and
T4, while maintaining normal TSH concentrations.
Cytokines such as TNF and IL-1, released by macrophagic
cells, have been proposed as the main mechanism for cancer
cachexia (Beutler & Cerami, 1988; Mahony & Tisdale, 1988;
Evans et al., 1989; Fong et al., 1989). Repeated administra-
tion or chronic infusion of TNF (Fong et al., 1989; Michie et
al., 1989; Darling et al., 1990) or IL-1 (Fong et al., 1989)
induces significant anorexia, weight loss, and loss of body
protein in rats and cachexia has been observed in nude mice
inoculated with CHO cells rendered TNF-producer by trans-
fection with human TNF cDNA (Oliff et al., 1987). The
observations concerning the presence of TNF and IL-1 in the
serum of cancer patients are inconsistent, however. Mol-
dawer et al. (1988) could not detect IL-1 and TNF bioac-
tivities in the plasma of weight-losing cancer patients; other
investigators have made similar observations (Scuderi et al.,
1986; Waage et al., 1986; Selby et al., 1987; Socher et al.,
1988b). By contrast, the presence of TNF has been observed
in the serum of children with acute lymphoblastic leukaemia
(Saarinen et al., 1990), in other cancer patients (Aderka et
al., 1985; Balkwill et al., 1987), and in cachectic tumour-
bearing rats (Stovroff et al., 1989). In our studies a fairly
constant elevation of TNF was detected in the plasma of
AH-130-bearing rats at days 4 and 10, indicating that there
was no apparent correlation with the tumour burden (at
variance with previous observations on sarcoma-bearing rats
[Stovroff et al., 1989]).
In short term cultures the AH-130 hepatoma cells released
PGE2 (cf. Trevisani et al., 1980; Strelkov et al., 1989), IL-1-
like factors, and TNF. The release ofcytokines was higher in
the exponential phase of growth, and thus positively cor-
related with the cell proliferation rate; consistently, TNF was
more elevated at day 4 than at day 10 both in the ascitic fluid
and in the blood plasma. Contrariwise, the release of PGE2
from AH-130 cells (and its plasma concentration as well) was
more elevated in the stationary phase; whether this finding
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implies some kind of mutual regulation between PGE2 and
cytokines (Goldings, 1986; Candela et al., 1991) was not
investigated. In addition, some IL-1 and TNF were produced
by ascites macrophages, while blood monocytes from
tumour-bearing rats spontaneously released TNF. The pos-
sibility that such activation of mononuclear phagocytes was
triggered by cytokines (Platanias & Vogelzang, 1990;
Jiiattela, 1991) originating from tumour cells should be con-
sidered. In AH-130 tumour hosts plasma PGE2 was elevated
and circulating TNF was detectable; although we failed to
demonstrate a corresponding elevation of IL-1 activity (data
not shown), the possibility that such activity was masked by
inhibitors or soluble cytokine receptors in the blood plasma
(Symons & Duff, 1991) cannot be excluded. This considera-
tion also applies to TNF (Gatanaga et al., 1990; Aderka et
al., 1991 and 1992), the levels of which might have been
underestimated. Other workers (Gelin et al., 1991) have made
partially similar observations: TNF and IL-1 are produced
by a tumour of non-lymphoid origin, the undifferentiated
sarcoma MCG 101, which causes cachexia in mice and also
elicits an acute phase response, yet no plasma elevation of
either cytokine could be demonstrated. Our present and
previous work (Tessitore et al., 1987a), on the other hand,
has clearly established that the AH-130 tumour quickly
elicited in the host rat an array of changes which are among
those characteristic of TNF and/or IL-1, such as increased
hepatic uptake and muscular release of amino acids with
reduced plasma levels of amino acids (Starnes et al., 1988;
Argiles et al., 1989), acceleration of whole body protein
turnover (Starnes et al., 1988), increased degradation and
depletion of muscle protein (Baracos et al., 1983; Tracey et
al., 1988; Fong et al., 1989; however, see: Kettlehut & Gold-
berg, 1988), transient liver hyperplasia (Feingold et al., 1988;
Fong et al., 1989; Mealy et al., 1990), augmented plasma
levels of triglycerides (Feingold & Grunfeld, 1987; Starnes et
al., 1988; Grunfeld et al., 1989), increased hepatic synthesis
and serum levels of cholesterol (Feingold & Grunfeld, 1987).
TNF or IL-1 can also activate a variety of other mechanisms
and cause the elevation ofplasma mediators such as cathech-
olamines and glucagon (Starnes et al., 1988; Rivier et al.,
1989), cortisol or corticosterone and ACTH (Del Rey &
Besedowsky, 1987; Starnes et al., 1988; Kehrer et al., 1988;
Tracey et al., 1988; Argiles et al., 1989; Rivier et al., 1989;
Sharp et al., 1989) and PGE2 (Dayer et al., 1985). By con-
trast, serum T3 and T4 decline after TNF (Imamura et al.,
1988) and were decreased in AH-130 tumour-bearers.
The role of cytokines in cancer cachexia may appear ques-
tionable in view of the observation that the administration of
a single cytokine renders most animals refractory to its effects
(Mahony & Tisdale, 1988; Socher et al., 1988a; Stovroff et
al., 1989; Tracey et al., 1988; Grunfeld et al., 1989; Darling et
al., 1990). This would imply, at least, that single cytokines
must act in concert with other cytokines or factors (Michie et
al., 1989) for cancer cachexia to develop. On the other hand,
cachexia could be attenuated in MCG 101 sarcoma-bearing
mice with anti-TNF antibodies (Sherry et al., 1989) or in rats
transplanted with a methylcholanthrene-induced sarcoma by
eliciting tolerance to TNF through repeated administration
of this cytokine at low dosage (Sheppard et al., 1990).
Besides the MCG 101 sarcoma (Gelin et al., 1991) and the
AH-130 hepatoma, also the Ehrlich ascites tumour cells pro-
duce TNF and circulating TNF can be detected in the host
mice (Tessitore L., Costelli, P., Baccino, F.M., unpublished
data). These observations are of special interest since
cytokine production by tumours was previously known only
for leukaemic cells (e.g., Platanias & Vogelzang, 1990;
Aguilar-Santelises et al., 1991). Thus for a few experimental
tumours, among those having the ability to elicit a rapidly
progressive cachexia, the host-wasting properties seem
associated, at least in part, with their ability to release
significant amounts ofcytokines, such as IL-1 and TNF (and
possibly of other factors such as PGE2).
Concluding remarks
The primary causative factors involved in the profound
metabolic perturbations that lead to cancer-induced cachexia
remain largely elusive as yet. Many different mechanisms
have been cited in different situations, either in humans or in
experimental models. In the present study a number of
potentially relevant parameters have been found to be altered
in rats bearing the AH-130 Yoshida ascites hepatoma and
further work is needed to clarify which, among them, may
have an initiating role. In any event, there seems no doubt
that cancer cachexia in the present model reflects complex
homeostatic perturbations and develops through the inter-
play of multiple factors (hormone changes, production of
cytokines, hypophagia), virtually all which seem to converge
in forcing protein metabolism, particularly in skeletal muscle,
into a hypercatabolic state.
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